# Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate

> **NCT00510354** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 28 (actual)

## Conditions studied

- Progressive Gastrointestinal Stromal Tumor

## Interventions

- **DRUG:** Imatinib mesylate

## Key facts

- **NCT ID:** NCT00510354
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2020-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00510354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00510354, "Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00510354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*